The aim of this paper is to report clinical characteristics, consequences, echocardiographic features, and pathological findings encountered in patients suffering from valvular disease associated with benfluorex exposure in a multicentre French registry.
Introduction
Fenfluramine and dexfenfluramine are sympathomimetic amines with anorectic action mediated through the activation of serotoninergic pathways in the brain. These drugs have been associated with the occurrence of cardiovascular effects including pulmonary arterial hypertension and valvular heart disease (VHD). 1 -4 As a result, they were, therefore, withdrawn from drug market in 1997. Benfluorex is a fenfluramine derivative. It has been marketed since 1976 in Asia, Europe, and South America and prescribed widely in patients with metabolic syndrome and type 2 diabetes mellitus as a drug with hypoglycaemic and hypolipidaemic action. 5 Five cases of pulmonary arterial hypertension and four isolated cases of severe VHDs have been recently reported in patients exposed to benfluorex. These observations suggest a link between benfluorex exposure and fibrotic valvular disease occurrence. 6 -9 Additional rationale was provided by two recent retrospective case -control studies which strongly suggest that patients treated with benfluorex may incur a risk of restrictive organic VHD.
The purpose of this retrospective study is to report clinical characteristics, consequences, echocardiographic features, and pathological findings encountered in patients suffering from suspected benfluorex-related valvular disease in a multicentre French registry.
Methods

Study population
Cases were identified as patients suffering from unexplained valvular disease with at least one moderate-to-severe valvular regurgitation or stenosis with a previous exposition to benfluorex for at least 3 months. Benfluorex treatment had to be prior to symptoms, cardiac murmur, or echocardiographic abnormalities.
Exclusion criteria were known or suspected primary or secondary cause of valvular disease: valvular prolapse, active or previous infective endocarditis, trauma, rheumatic heart disease or history of rheumatic fever, radiation-induced valvular disease, congenital disease, associated connective and/or vasculitis disease, ischaemic, ventricular dilatation associated regurgitation, or hypertrophic cardiomyopathy.
Cardiology departments of all French university hospitals, of important private clinics, and all French cardiothoracic surgery departments were contacted by letter. Information concerning the study and a standardized questionnaire were available at the website of the French Society of Cardiology. Nineteen patients from two previous retrospective case -control studies were also included. 10, 11 Some patients of these studies were excluded mainly because of lack of detailed echocardiographic data or, in few cases, because of uncertainty about the respective role of benfluorex and dexfenfluramine in cardiac disease. Data were obtained by chart review, clinical interviews, and/or telephone calls to physician and patients. We gathered information concerning clinical characteristics, medications, echocardiographic parameters, surgery type, and histology. Daily doses of benfluorex, total duration of treatment, cumulative dose, and time between initiation of benfluorex and diagnosis of valvular disease were recorded. Exposition to other drugs known to induce valvular disease was also recorded (ergot alkaloids, cabergoline, MDMA, fenfluramine/phentermine, dexfenfluramine, and pergolide).
Echocardiography
All echocardiography records were analysed by two experienced observers in reference centres, and disagreements were resolved by consensus. Standard two-dimensional measurements [left ventricular (LV) enddiastolic and end-systolic diameters, interventricular septum, and posterior wall thickness] were obtained from parasternal long-axis views. Left atrium surface was calculated by planimetry from apical four-chamber views. LV ejection fraction was calculated using the Simpson method. Pulmonary artery systolic pressure was estimated using the simplified Bernoulli equation. Pulmonary hypertension was defined as a pulmonary artery systolic pressure above 50 mmHg. Stenosis and regurgitations were graded as mild, moderate, or severe by a quantitative or semi-quantitative approach according to the recent guidelines. 12 -14 Whenever possible, the proximal isovelocity surface area method was used to quantify more precisely the severity of regurgitations by measuring effective regurgitant orifice (ERO) area and regurgitated volume. Mitral, tricuspid, and pulmonary regurgitations were considered significant if severity was at least moderate, and for aortic ones, if severity was at least mild. No nominative data were collected, and the study had no impact on patient's management.
Therefore, according to the French regulations, a formal consent was not obtained from participants.
Statistical analysis
The characteristics of cases were described using mean and standard deviation for continuous variable, and proportion for categorical variables.
Patients were separated into two groups: those suffering from at least one severe valvular regurgitation or stenosis vs. those suffering from mild and moderate ones. Benfluorex treatment duration, daily dose, and cumulative dose (mean value + 1 standard deviation) were compared between groups by Student's t-tests.
In order to assess dose -effect relationship from another perspective, patients were also separated into three groups:
Group 1: patients suffering from VHD involving only one valve. Group 2: patients suffering from VHD involving two valves. Group 3: patients suffering from VHD involving three valves.
Benfluorex treatment duration, daily dose, and cumulative dose (mean value + 1 standard deviation) were compared between groups by the Kruskal -Wallis test.
For all tests, a P-value of ,0.05 was considered statistically significant. All P-values are results of the two-tailed test. Statistical analysis was performed with SPSS 13.0 (SPSS Inc., Chicago, IL, USA). 
Results
Clinical and demographic data
There was a clear gender discrepancy with 35 women (87.5%) for 5 men (12.5%). Mean age at diagnosis was 57 + 9 years. Most patients presented obesity with a mean body mass index (BMI) of 30 + 7 kg/m 2 . Nineteen (47.5%) were past or active smokers, 19 (47.5%) presented with hypercholesterolaemia, and 19 (47.5%) with hypertension ( Table 1) . On admission, 25 patients (62.5%) complained of moderate (NYHA class I and II) and 15 (37.5%) of severe heart failure symptoms (NYHA class III and IV).
Treatment
Benfluorex mean daily dose was 415 + 131 (150 -900) mg with the mean total therapy duration of 72 + 53 (3-216) months. Resulting mean cumulative dose was 910 + 675 (13-2916) g. Delay between beginning of benfluorex exposition and VHD diagnosis was 66 + 41 (12-204) months. Mean daily dose, mean therapy duration, and mean cumulative dose were not significantly different in cases with and without severe regurgitations. There was also no significant association with the number of valves involved ( Table 1) .
Concerning other treatments known to induce fibrotic valvular disease, seven patients (17.5%) were previously exposed to appetite suppressant (fenfluramine, phentermine and derivatives, diethylpropion). However, all patients were free from clinical or echocardiographical signs of valvular disease in the interval between these drugs and benfluorex exposition. Eight patients (20%) have been exposed to selective serotonin-reuptake inhibitors.
Echocardiograpic findings
Mitral regurgitation (MR) was identified in 39 patients out of 40 (97.5%). It was mostly severe (20 cases, 50%). Mild and moderate MR were found respectively in 6 and 13 cases (15 and Valvular heart disease associated with benfluorex therapy reported. Common findings were leaflet thickening, retraction and reduced mobility, especially on posterior leaflet. Subvalvular apparatus was also thickened with shortening of the chordae tendineae, causing a tenting of leaflets and loss of coaptation with central regurgitation (Figure 1 ). Calcifications were rarely described, and minimal commissural fusions were sometimes observed ( Table 2) . Aortic regurgitation (AR) was identified in 35 patients (87.5%). It was quantified as mild in 6 patients (15%), moderate in 20 patients (50%), and severe in 9 patients (22.5%). No significant aortic stenosis was found. Aortic valve involvement was characterized by leaflet retraction, thickening, decreased mobility, and the loss of coaptation resulting in central regurgitation (Figure 2) .
Moderate and severe tricuspid regurgitation (TR) were identified in 11 cases (27.5%) and were mostly secondary to pulmonary artery hypertension and annulus dilatation. Organic TR was identified in four cases. Tricuspid valve features were quite similar to mitral with decreased mobility, predominantly on septal leaflet (Figure 3) .
Involvement of pulmonary valve associated with TR and MR was described in one case. Simultaneous involvement of two valves, at least mild AR, moderate MR, PR and TR, or stenosis, was identified in 21 cases (52.5%) and 3 valves in 10 cases (25%). Isolated valve abnormalities were found in nine cases (22.5%). The most common association was AR and MR, both involved in 29 patients (72.5%).
Mean LV ejection fraction was 0.59 + 0.08, with mean LV enddiastolic diameter at 57 + 6 mm and mean LV end-systolic diameter at 37 + 6 mm. Mean LV end-diastolic and end-systolic diameters normalized to body surface area were, respectively, 31 + 5 and 20 + 4 mm/m 2 . Mean left atrium surface was 25 + 6 mm 2 and mean systolic pulmonary arterial pressure was 47 + 15 mmHg, with pulmonary artery pressure above 50 mmHg in 16 cases (40%). Baseline echocardiograms without signs of valvular disease were available in three patients. They were considered 'normal'. After benfluorex exposure, severe restrictive MR were identified in all of them and AR were described in two of them (one moderate and one severe). LV dilatation, slight LV ejection fraction impairment, and pulmonary hypertension were constant. Mean LV end-diastolic diameter was 58 + 5 mm, LV end-systolic diameter was 39 + 6 mm, and pulmonary artery systolic pressure was 65 + 18 mmHg. 
Outcomes
Fifteen patients (37.5%) underwent valvular surgery. Isolated mitral reconstruction was possible in one case (2.5%) and isolated mitral replacement was performed in two cases (5%). Isolated aortic valve replacement was performed in one case (2.5%). Mitral and aortic combined replacement was the most frequent operation (10 cases, 25%). This type of surgery was associated with tricuspid valve reconstruction in one case (2.5%). Two patients died (5%): one died subsequently to valvular surgery complications and another died of hypoxic circulatory arrest while on medical treatment. Other patients were stabilized with medical treatment (Table 3) .
Pathology findings
Gross pathological and histopathological examinations were available in five cases (12.5%). Macroscopical aspect of patient's explanted aortic and mitral valve was glistening white leaflet and chordae with diffuse thickening and shortening of the sub-valvular apparatus and fused chordae tendineae (Figure 3) . Valvular histopathological examination demonstrated leaflet tissue thickening by abundant extracellular matrix of glycosaminoglycans and collagene with proliferation of myofibroblasts, smooth muscle cells, few calcifications, and no pronounced inflammation. These deposits resulted in plaque-like encasement of the leaflets without modification of valve architecture (Figure 4) .
Discussion
Unlike other amphetamine derivatives, which were withdrawn from drug market at the end of the nineties, benfluorex was widely prescribed in Europe and Asia from 1976 to 2009 for the treatment of metabolic syndrome or type 2 diabetes mellitus. Since 2003, five cases of pulmonary arterial hypertension and four cases of unexplained fibrotic valvular disease in patient exposed to benfluorex were reported. 6 -9 Recently, two case-control studies using similar design drew the same conclusions: rates of exposition to benfluorex were dramatically higher in patients with restrictive MR of unclear aetiology compared with matched control patients (36.4 vs. 4.5% for Tribouilloy et al. 10 and 70.4 vs. 5.6% for Frachon et al.
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) These studies strongly suggest that patients treated with benfluorex might incur a risk of restrictive organic VHD. As a consequence, French authorities have withdrawn Valvular heart disease associated with benfluorex therapy benfluorex from the national market on 26 November 2009, 15 and
European Medicines Agency has recommended its withdrawal in European Union on 18 December 2009. 16 Observations collected in this multicentre registry had a quite homogeneous presentation: most patients were middle aged women with obesity and/or diabetes mellitus; exposed to benfluorex for a mean duration of 72 + 53 months. Most of them were suffering from symptomatic cardiac failure with severe presentation in more than one-third of them.
Echocardiographic analysis also identified homogeneous features in our patients. Common findings were leaflets thickening and retraction with inconstant minimal commissural fusion and rare calcifications. Sub-valvular apparatus was thickened and shortened with fused chordae tendineae. These injuries resulted mainly in the loss of leaflets coaptation and predominant regurgitation.
Indeed, MR and AR were the most frequent features, whereas significant stenoses were uncommon. In contrast with previous studies. 10 we identified four cases (10%) with organic tricuspid valve involvement and one case (2.5%) with organic pulmonary valve dysfunction. Multiple fibrotic valve diseases were noted in more than 75% of the patients, displaying predominantly association of aortic and MRs (72.5%) and leading to combined valve surgery in 11 cases (27.5%). Pathological findings in five patients were uniform: valvular tissue thickening by abundant extracellular matrix of glycosaminoglycans and collagene with proliferation of myofibroblasts and smooth muscle cells, few calcifications, and no pronounced inflammation. The underlying valve structure was unchanged.
All these morphological and histological features were similar to those reported after exposure to other appetite-suppressant, ergot alkaloids, and pergolide. 17, 18 This suggests a common pathophysiological mechanism. On one hand, all these drugs interact with serotonin metabolism, and on the other hand, this kind of valvular abnormalities was also described in malignant carcinoid syndrome. According to the initial hypothesis, these treatments may increase circulating serotonin concentrations by interfering with serotonin transporter proteins and thereby induce valvulopathy. 17 The predilection for right-sided valves in carcinoid disease being related to the serotonin-rich blood that enters the right atrium directly from the liver and the subsequent partial pulmonary degradation of serotonin. However, several studies demonstrated that chronic fenfluramine and phentermine use lowers plasma and platelets serotonin levels. 19 -21 These findings indicate that drug-induced valvular disease (DIVD) may be caused by direct drug stimulation of serotonin receptor subtypes rather than increases in serotonin plasma levels.
The serotonin receptor 5HT2B is found in both aortic and mitral valves and is known to stimulate mitogenesis on fibroblast and smooth muscle cells. Activation of this receptor causes dissociation of G-proteins, which leads to activation of protein kinases and enhances transforming growth factor b activity. The result is cell proliferation with subsequent valvular disease. 18 Methylergonovine, an active metabolite of ergotamine and methysergide, and pergolide have high affinity for 5HT2B receptors. Cabergoline and MDMA (ecstasy) are potent agonists at the 5HT2B receptor, whereas lisuride is antagonists. Although fluoxetine interacts with serotonin metabolism, it has low affinity for this receptor. This may explain why this drug and other selective serotonin reuptake-inhibitors are not known to cause DIVD. 22, 23 Norfenfluramine, a metabolite of fenfluramine and benfluorex, also has high affinity for 5HT2B receptors. These findings provide additional rationale to benfluorex-related VHD. 23 Since morphological abnormalities are quite similar, wrong diagnosis of rheumatic disease may be done in patients suffering from DIVD. Common presentation in chronic rheumatic valvular disease includes alteration of underlying valve architecture with frequent calcification, leaflet nodules, commissural fusion, and significant valvular stenosis.
14 Their absence in patients with suspected, but not proven, rheumatic valvular disease should lead to diagnosis reconsideration with investigation on previous medications. In our study, patients were supposed to be free from rheumatic heart disease history, but these assumptions relied on patients' or physicians' declarations that might be inexact. Furthermore, some patients were previously exposed to appetite suppressant, fenfluramine, phentermine, and derivatives or diethylpropion. However, all patients with clinical or echocardiographic signs of VHD before benfluorex exposition were not kept in the study. Moreover, dexfenfluramine was withdrawn from the market in 1997, 4 years before the earliest diagnosis of DIVD in the present study. Consequently, dexfenfluramine is unlikely to have played a role among these patients since valvular regurgitation has been suggested as a dexfenfluramine's short-term effect. 8 Results from previous studies show that drug dose and treatment duration increase the risk of developing the disease and its severity. 4, 17 This association was not clearly found in our series of benfluorex-related valvular disease. Benfluorex daily dose, exposition duration, or cumulative dose was not significantly associated with an increase in severity or in the number of valve involved. Because of the retrospective design of the study, precise timing dose and duration of exposure was probably not always accurate. Numerous factors are involved in pathophysiology with complex interactions between serotonin transporters, serotonin plasma levels, and 5HT2B receptors. This interrelation and polymorphisms in gene expression could partly explain the heterogeneous individual susceptibility. Moreover, we selected only patient with moderateto-severe valvular disease. This may also explain the long 5 years gap between the initiation of benfluorex therapy and the diagnosis of DIVD in our study group. According to the European Commission, morphological and functional valvular heart abnormalities can be seen after an average of 328 days of exposure. 24 In contrast, studies that investigated DIVD by fenfluramine-phentermine and dexfenfluramine had much shorter treatment duration, ranging between 71 days and 13 months. 2,25,26 Dose-effect relationship must be evaluated in larger scale studies taking into account mild valvular regurgitations and stenosis to be relevant. The natural history of DIVD remains unclear. Although regression of valvular lesions after the end of treatment has been reported, 17 we have not gathered enough data concerning follow-up to resolve this important question in patients suffering from VHD associated with benfluorex therapy. Therefore, further prospective studies are needed.
In our population, this valvular disease had serious clinical consequences as near half of the patients were suffering from severe heart failure symptoms. More than one-third of them needed valvular surgery because of symptoms, pulmonary artery hypertension, and/or LV dysfunction. Two patients directly died from this disease.
However, due to hospital recruitment of symptomatic patients, these observations represent only the most severe presentation of this valvular disease. Adding the fact that DIVD may be confounded with rheumatic valvular disease, the real impact of this widely used drug in the general population is probably mis-estimated and we can expect an under-diagnosis of minor and asymptomatic forms. As this is not a controlled study and data were collected retrospectively, some biases could occur in the analysis which might overestimate the severity of VHD and association with benfluorex therapy. Therefore, prospective clinical and echocardiographic screening in outpatients previously exposed to benfluorex should be performed.
Conclusion
Analysis of our 40 cases of VHD associated with benfluorex demonstrates that clinical consequences may be serious with severe heart failure symptoms that may lead to surgical treatment and even death. Echocardiographic features include leaflets and valvular sub-apparatus thickening and retraction, with chordae-tendineae fusions. The prevalence of this disease is probably underestimated since it may be interpreted as rheumatic valvular disease and not diagnosed in asymptomatic patients. Diagnosis should be reconsidered in VHD of unclear aetiology in patient exposed to benfluorex, especially in the absence of commissural fusion, calcifications, or significant stenosis. Evaluation of prevalence, dose-effect relationship, and potential valvular injuries reversal after treatment withdrawal needs larger scale prospective studies.
